Innovation Articles

31. A State Of Stress: Developing Therapeutics Rooted In Cell Behavior 2/24/2026

    We caught up with Yerem Yeghiazarians, CEO of Soley Therapeutics, to discuss how capturing the complexity of disease requires going beyond a single target.

32. Beyond KRAS G12C: New Approaches For Drugging The Undruggable 2/20/2026

    RAS was considered among the holy grail of oncology targets, but over the past decade, this has started to change. A second wave is making its way through R&D to address current shortcomings.

33. Building Inclusivity Into Early-Stage Preclinical Drug Discovery 2/13/2026

    Systematically reporting both ancestry and sex as standard biological variables may foster more representative and translationally relevant approaches to drug discovery.

34. From Cyclization To The Clinic: The Rising Era Of Cyclic Peptide Therapeutics 1/28/2026

    The pharmaceutical industry is currently experiencing a golden era for cyclic peptide therapeutics.

35. Targeting Underlying Biology: Novel Combination Therapies For Chronic Disease 1/26/2026

    Combination therapies that incorporate cannabinoids and psychedelics signal an important shift in how complex chronic diseases are being approached. 

36. Schrödinger's Equation Turns 100: How Quantum Chemistry Is Improving Drug Discovery 1/23/2026

    On January 26th, 2026 as we celebrate this centennial milestone of Schrödinger’s Equation, it’s worth asking: What does quantum mechanics mean for drug discovery and biomolecular simulations?

37. Annual Reflections And Predictions From The Editors' Roundtable 1/6/2026

    Understanding the full scope of the life science industry has never been more critical. Ray Dogum, Chief Editor of Drug Discovery Online, joins the Life Science Connect Editors’ Roundtable on a special episode of Better Biopharma podcast.

38. Engineering Therapeutics With A Structural Approach 12/30/2025

    Faraz A. Choudhury, CEO of Immuto Scientific, discusses target proteins and their adoption of disease-specific conformations that could increase how therapeutics discriminate between diseased and healthy tissues.

39. Room For Improvement: Reformulating Existing Therapeutics 12/30/2025

    We caught up with Jed Litwiniuk, CEO, and Uwe Tigör, CMO, to talk about Auxilius Pharma’s work to improve and reformulate a treatment for chronic stable angina pectoris.

40. The Unlikely Weapon Against Fentanyl: Your Immune System 12/23/2025

    ARMR Sciences Inc. has developed a vaccine designed with a novel adjuvant, dmLT, to neutralize fentanyl in the bloodstream before it reaches the central nervous system and binds to μ-opioid receptors (MORs).